Growth Metrics

Vanda Pharmaceuticals (VNDA) Net Cash Flow (2016 - 2025)

Vanda Pharmaceuticals' Net Cash Flow history spans 16 years, with the latest figure at $14.8 million for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 632.76% to $14.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$17.5 million, a 47.55% increase, with the full-year FY2025 number at -$17.5 million, up 47.55% from a year prior.
  • Net Cash Flow hit $14.8 million in Q4 2025 for Vanda Pharmaceuticals, up from -$10.8 million in the prior quarter.
  • Over the last five years, Net Cash Flow for VNDA hit a ceiling of $219.1 million in Q1 2023 and a floor of -$204.1 million in Q2 2023.
  • Historically, Net Cash Flow has averaged $1.2 million across 5 years, with a median of -$4.7 million in 2021.
  • Biggest five-year swings in Net Cash Flow: surged 5078.73% in 2022 and later crashed 2224.23% in 2023.
  • Tracing VNDA's Net Cash Flow over 5 years: stood at $1.6 million in 2021, then surged by 5078.73% to $85.4 million in 2022, then crashed by 155.61% to -$47.5 million in 2023, then skyrocketed by 104.25% to $2.0 million in 2024, then soared by 632.76% to $14.8 million in 2025.
  • Business Quant data shows Net Cash Flow for VNDA at $14.8 million in Q4 2025, -$10.8 million in Q3 2025, and -$30.9 million in Q2 2025.